Patents by Inventor Paula Maria Wilhelmina van Helden

Paula Maria Wilhelmina van Helden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AML ANTIGENS AND USES THEREOF
    Publication number: 20230235018
    Abstract: The present invention provides novel compounds comprising an antigen of AML cells, and uses thereof.
    Type: Application
    Filed: October 27, 2022
    Publication date: July 27, 2023
    Inventors: Hergen SPITS, Marijn Aletta GILLISSEN, Martijn KEDDE, Mette Deborah HAZENBERG, Paula Maria Wilhelmina VAN HELDEN, Wouter POS
  • AML antigens and uses thereof
    Patent number: 11524989
    Abstract: The present invention provides novel compounds comprising an antigen of AML cells, and uses thereof.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: December 13, 2022
    Assignee: KLING BIOTHERAPEUTICS B.V.
    Inventors: Hergen Spits, Marijn Aletta Gillissen, Martijn Kedde, Mette Deborah Hazenberg, Paula Maria Wilhelmina van Helden, Wouter Pos
  • Therapeutic Anti-CD9 Antibody
    Publication number: 20220064323
    Abstract: The present invention provides novel binding compounds and therapeutic applications thereof.
    Type: Application
    Filed: September 16, 2021
    Publication date: March 3, 2022
    Inventors: Hergen SPITS, Paula Maria Wilhelmina VAN HELDEN, Remko SCHOTTE, Wouter POS, Christien FATMAWATI, Danïel Michiel GO, Koen WAGNER, Julien Christian VILLAUDY
  • Therapeutic anti-CD9 antibody
    Patent number: 11136407
    Abstract: The present invention provides novel binding compounds and therapeutic applications thereof.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: October 5, 2021
    Assignee: AIMM Therapeutics B.V.
    Inventors: Hergen Spits, Paula Maria Wilhelmina Van Helden, Remko Schotte, Wouter Pos, Christien Fatmawati, Danïel Michiel Go, Koen Wagner, Julien Christian Villaudy
  • EX VIVO ANTIBODY PRODUCTION
    Publication number: 20200149007
    Abstract: The present invention provides means and methods for producing improved ex vivo B cell cultures with a short doubling time.
    Type: Application
    Filed: September 19, 2019
    Publication date: May 14, 2020
    Inventors: PAULA MARIA WILHELMINA VAN HELDEN, Mark Jeroen KWAKKENBOS, Hergen Spits, Tim Beaumont
  • Therapeutic Anti-CD9 Antibody
    Publication number: 20190023803
    Abstract: The present invention provides novel binding compounds and therapeutic applications thereof.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 24, 2019
    Applicant: AIMM Therapeutics B.V.
    Inventors: Hergen SPITS, Paula Maria Wilhelmina VAN HELDEN, Remko SCHOTTE, Wouter POS, Christien FATMAWATI, Danïel Michiel GO, Koen WAGNER, Julien Christian VILLAUDY
  • AML ANTIGENS AND USES THEREOF
    Publication number: 20180170998
    Abstract: The present invention provides novel compounds comprising an antigen of AML cells, and uses thereof.
    Type: Application
    Filed: June 24, 2016
    Publication date: June 21, 2018
    Inventors: Hergen SPITS, Marijn Aletta GILLISSEN, Martijn KEDDE, Mette Deborah HAZENBERG, Paula Maria Wilhelmina van HELDEN, Wouter POS
  • FVIII PEPTIDES FOR IMMUNE TOLERANCE INDUCTION AND IMMUNODIAGNOSTICS
    Publication number: 20170267743
    Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+ T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.
    Type: Application
    Filed: November 2, 2016
    Publication date: September 21, 2017
    Inventors: Katharina Nora Steinitz, Paula Maria Wilhelmina van Helden, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
  • FVIII peptides for immune tolerance induction and immunodiagnostics
    Patent number: 9512198
    Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+ T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: December 6, 2016
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Katharina Nora Steinitz, Paula Maria Wilhelmina van Helden, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
  • FVIII PEPTIDES FOR IMMUNE TOLERANCE INDUCTION AND IMMUNODIAGNOSTICS
    Publication number: 20150203567
    Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.
    Type: Application
    Filed: January 23, 2015
    Publication date: July 23, 2015
    Inventors: Katharina Nora Steinitz, Paula Maria Wilhelmina van Helden, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
  • FVIII peptides for immune tolerance induction and immunodiagnostics
    Patent number: 8969524
    Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+ T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: March 3, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Katharina Nora Steinitz, Paula Maria Wilhelmina van Helden, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
  • FVIII PEPTIDES FOR IMMUNE TOLERANCE INDUCTION AND IMMUNODIAGNOSTICS
    Publication number: 20120135019
    Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+ T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.
    Type: Application
    Filed: October 27, 2011
    Publication date: May 31, 2012
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Katharina Nora Steinitz, Paula Maria Wilhelmina van Helden, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich